ClinicalTrials.gg
CompletedNCT01434888Updated Jun 8, 2012

Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops

A Phase 1 interventional study of Preservative free tafluprost 0.0015% eye drops and Preservative free timolol 0.5% eye drops in Healthy Volunteers, sponsored by Santen Oy. Completed at 1 site in Finland. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-06-08.

Sponsored by Santen Oy (part of Santen Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The objective of this study is to investigate the pharmacokinetics, safety and tolerability of the preservative-free fixed-dose combination of tafluprost 0.0015% and timolol 0.5% (FDC) to those of preservative-free tafluprost 0.0015% and timolol 0.5% eye drops in healthy volunteers.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • pharmacokinetics
03

In context

Lead sponsor

Santen Oy is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 45 years
  • Good general health
  • Meet best corrected ETDRS visual acuity

Exclusion criteria

Exclusion Criteria:

  • Significant systemic or ocular disease
  • History of eye surgery, including refractive surgery
  • Allergy or to study drug
  • Low heart rate (\<50 bpm)
  • low blood pressure
  • Asthma
  • Bradycardia
  • Use of contact lenses within one week prior to screening or during the study
  • Clinically significant obesity ( > 30 kg/m2)
  • Blood donation within 2 months prior to screening
  • Females who are pregnant or lactating and females not using adequate
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
15 participants (actual)

Study arms

  • Active comparator
    Tafluprost 0.0015%

    Drug: Preservative free tafluprost 0.0015% eye drops

  • Active comparator
    Timolol 0.5%

    Drug: Preservative free timolol 0.5% eye drops

  • Experimental
    Fixed-dose combination of tafluprost 0.0015% and timolol 0.5%

    Drug: Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops

Interventions

  • DrugPreservative free tafluprost 0.0015% eye drops

    Preservative free tafluprost eye drops will be administered once daily at 09:00 into both eyes for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.

  • DrugPreservative free timolol 0.5% eye drops

    Preservative free timolol eye drops will be administered into both eyes twice daily at 9:00 and 21:00 for seven days

  • DrugPreservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops

    Preservative free fixed-dose combination eye drops will be administered into both eyes once daily at 9:00 for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics after single and repeated administration of preservative-free FDC, tafluprost and timolol eye drops.

    The primary evaluation of pharmacokinetics will be based on the plasma concentration of tafluprost acid and timolol.

    Time frame: There are 3 cross-over treatment periods, plasma concentrations will be measured on Day 1 and Day 7

Secondary outcomes

  1. Safety and tolerability after single and repeated administration of preservative-free FDC, tafluprost and timolol eye drops.

    The changes from screening/baseline will be evaluated in following variables:visual acuity, IOP, biomicroscopy and ophthalmoscopy findings and drop discomfort. Adverse events will be followed from screening to post-study visit.

    Time frame: Day 1 and Day 7 of treatment periods I, II and III.

07

Study locations

1 site
  • Kuopio University Hospital Eye Clinic
    Kuopio, 70200, Finland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2011
First posted
Sep 15, 2011
Start
Sep 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Last update
Jun 8, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01434888
Lead sponsor
Santen Oy
Responsible party
Sponsor
First posted
Sep 15, 2011
Start date
Sep 2011
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Jun 8, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion